| Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion RD Leone, L Zhao, JM Englert, IM Sun, MH Oh, IH Sun, ML Arwood, ... Science 366 (6468), 1013-1021, 2019 | 922 | 2019 |
| Metabolism of immune cells in cancer RD Leone, JD Powell Nature reviews cancer 20 (9), 516-531, 2020 | 613 | 2020 |
| Targeting adenosine for cancer immunotherapy RD Leone, LA Emens Journal for immunotherapy of cancer 6, 1-9, 2018 | 510 | 2018 |
| Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma R Rangwala, R Leone, YC Chang, LA Fecher, LM Schuchter, A Kramer, ... Autophagy 10 (8), 1369-1379, 2014 | 400 | 2014 |
| Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells MH Oh, IH Sun, L Zhao, RD Leone, IM Sun, W Xu, SL Collins, AJ Tam, ... The Journal of clinical investigation 130 (7), 3865-3884, 2020 | 325 | 2020 |
| A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy RD Leone, YC Lo, JD Powell Computational and structural biotechnology journal 13, 265-272, 2015 | 280 | 2015 |
| Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention IV Zhigaltsev, N Maurer, QF Akhong, R Leone, E Leng, J Wang, ... Journal of controlled release 104 (1), 103-111, 2005 | 260 | 2005 |
| Targeting metabolism to regulate immune responses in autoimmunity and cancer CH Patel, RD Leone, MR Horton, JD Powell Nature reviews Drug discovery 18 (9), 669-688, 2019 | 248 | 2019 |
| Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine … RD Leone, IM Sun, MH Oh, IH Sun, J Wen, J Englert, JD Powell Cancer immunology, immunotherapy 67, 1271-1284, 2018 | 176 | 2018 |
| Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity SC Semple, R Leone, J Wang, EC Leng, SK Klimuk, ML Eisenhardt, ... Journal of pharmaceutical sciences 94 (5), 1024-1038, 2005 | 126 | 2005 |
| Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy RC Augustin, RD Leone, A Naing, L Fong, R Bao, JJ Luke Journal for immunotherapy of cancer 10 (2), 2022 | 78 | 2022 |
| Autophagy: a targetable linchpin of cancer cell metabolism RD Leone, RK Amaravadi Trends in Endocrinology & Metabolism 24 (4), 209-217, 2013 | 77 | 2013 |
| Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug R Rais, KM Lemberg, L Tenora, ML Arwood, A Pal, J Alt, Y Wu, J Lam, ... Science advances 8 (46), eabq5925, 2022 | 71 | 2022 |
| Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation WB Dalton, E Helmenstine, N Walsh, LP Gondek, DS Kelkar, A Read, ... The Journal of clinical investigation 129 (11), 4708-4723, 2019 | 61 | 2019 |
| Lipid nanoparticle delivery systems to enable mRNA-based therapeutics SC Semple, R Leone, CJ Barbosa, YK Tam, PJC Lin Pharmaceutics 14 (2), 398, 2022 | 57 | 2022 |
| Something in the air: hyperoxic conditioning of the tumor microenvironment for enhanced immunotherapy RD Leone, MR Horton, JD Powell Cancer cell 27 (4), 435-436, 2015 | 47 | 2015 |
| Fueling the revolution: targeting metabolism to enhance immunotherapy RD Leone, JD Powell Cancer immunology research 9 (3), 255-260, 2021 | 26 | 2021 |
| Glutaminase inhibition with CB-839 enhances anti-tumor activity of PD-1 and PD-L1 antibodies by overcoming a metabolic checkpoint blocking T cell activation M Gross, J Chen, J Englert, J Janes, R Leone, A MacKinnon, F Parlati, ... Cancer Research 76 (14_Supplement), 2329-2329, 2016 | 22 | 2016 |
| Glutamine metabolism inhibition has dual immunomodulatory and antibacterial activities against Mycobacterium tuberculosis S Parveen, J Shen, S Lun, L Zhao, J Alt, B Koleske, RD Leone, R Rais, ... Nature communications 14 (1), 7427, 2023 | 11 | 2023 |
| Metabolic reprogramming of tumor-associated macrophages using glutamine antagonist JHU083 drives tumor immunity in myeloid-rich prostate and bladder cancers M Praharaj, F Shen, AJ Lee, L Zhao, TR Nirschl, D Theodros, AK Singh, ... Cancer Immunology Research, OF1-OF22, 2024 | 10 | 2024 |
